Portal de Periódicos da CAPES

Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients

2024; Elsevier BV; Volume: 5; Issue: 9 Linguagem: Inglês

10.1016/j.medj.2024.05.017

2666-6359

Mireia Bernabéu-Gimeno, Marco Pardo-Freire, Benjamin K. Chan, Paul E Turner, Ana Gil-Brusola, Santiago Pérez‐Tarazona, Laura Carrasco‐Hernández, Esther Quintana-Gallego, Pilar Domingo‐Calap,

Advanced biosensing and bioanalysis techniques

Cystic fibrosis (CF) patients are prone to recurrent multi-drug-resistant (MDR) bacterial lung infections. Under this scenario, phage therapy has been proposed as a promising tool. However, the limited number of reported cases hampers the understanding of clinical outcomes. Anti-phage immune responses have often been overlooked and only described following invasive routes of administration.